US has chosen drugs to negotiate for Medicare
The negotiations will take place in 2025 and the eventual negotiated prices will take effect in 2027, the department writes in a press release.
The selected drugs include the diabetes drug Ozempic, the weight loss drug Wegovy and the diabetes pill Rybelsus from the Danish pharmaceutical company Novo Nordisk. Medicines from Pfizer, GSK, Teva and Abbvie are also on the list.
The companies were selected because they are already part of Medicare Part D and because their drugs are among those the program spends the most money on. The selected medicines are also widely used by older Americans.
"Last year, we proved that negotiating lower drug prices works. Now we plan to build on that by negotiating lower prices for 15 additional key medicines for older adults," said US Secretary of Health and Human Services Xavier Becerra.
Companies have until February 28 to decide whether or not to participate.
Go to the original article.
Contact us to request a correction